| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | -4,145 | -3,406 | -4,303 | 40,397 |
| Gain on derecognition of lease liabilities upon contract assignment | NaN | 2,651 | 0 | 1,167 |
| Stock-based compensation expense | 749 | 1,517 | 1,225 | 7,010 |
| Depreciation and amortization expense | 29 | 49 | 36 | 2,031 |
| Accretion of liability related to sale of future revenues | 814 | 878 | 891 | 1,809 |
| Amortization (accretion) of investment premiums (discounts) | 0 | -84 | 83 | -258 |
| Non-cash operating lease expense | 185 | 263 | 320 | 4,413 |
| Loss on impairment of lease right-of-use asset | 0 | 0 | 0 | 4,130 |
| Other non-cash items, net | 49 | -457 | 4 | 547 |
| Accounts receivable | -1,253 | -660 | 1,913 | -1,482 |
| Inventories | 0 | 0 | 0 | -10,655 |
| Other current assets | 1,336 | -326 | 367 | -6,211 |
| Other assets | 15 | 27 | -46 | 4 |
| Accounts payable | 510 | -191 | -983 | -3,066 |
| Accrued compensation | -642 | -796 | -485 | -4,037 |
| Accrued research and development expenses | -41 | -260 | -629 | -7,013 |
| Other current liabilities | -166 | -839 | -2,239 | -1,438 |
| Deferred revenue | -32 | -295 | -596 | -93,485 |
| Operating lease liabilities | -285 | -552 | -711 | -4,190 |
| Other long-term liabilities | 0 | 0 | 0 | 1 |
| Net cash used in operating activities | -3,073 | -5,697 | -9,787 | -35,456 |
| Purchases of short-term investments | NaN | 0 | 2,466 | 5,419 |
| Purchases of property and equipment | NaN | 0 | 0 | 0 |
| Proceeds from sale of property and equipment | NaN | 555 | 44 | 349 |
| Proceeds from maturities and sales of short-term investments | 0 | 7,885 | 1 | 17,199 |
| Net cash provided by investing activities | 0 | 8,440 | -2,421 | 12,129 |
| Proceeds from employee stock awards | NaN | 22 | 12 | 1 |
| Other financing activities, net | NaN | 0 | 0 | -1 |
| Proceeds from sale of common stock and pre-funded warrants in registered direct offerings, net | NaN | 0 | -461 | 15,304 |
| Proceeds from issuance of common stock through atm facilities, net | 2,951 | -25 | 1,496 | 0 |
| Taxes paid related to net share settlement of restricted stock units | NaN | NaN | NaN | 0 |
| Principal payments on finance lease obligations | 0 | 0 | 0 | 250 |
| Net cash provided by (used in) financing activities | 2,951 | -3 | 1,047 | 15,054 |
| Increase (decrease) in cash, cash equivalents and restricted cash | -122 | 2,740 | -11,161 | -8,273 |
| Cash, cash equivalents and restricted cash at beginning of period | 8,482 | 5,742 | 25,176 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 8,360 | 8,482 | 5,742 | NaN |
Atara Biotherapeutics, Inc. (ATRA)
Atara Biotherapeutics, Inc. (ATRA)